The study involved 2,974 Japanese-American men, ages 71 to 91, who were dementia-free from 1991 to 1993 at the start of the study.
A total of 134 men developed Alzheimer's disease after an average of 6 years, while 44 developed vascular dementia. Upon further analysis, higher levels of estradiol were associated with an increased risk for Alzheimer's. With each standard deviation increase, the risk for Alzheimer's rose by 25%.
Researchers hypothesize that the association between impaired brain function and estradiol could be due to increased aromatase activity in the brain, which might cause cognitive decline.
Or it could be the other way around. Neurodegeneration from Alzheimer's could lead to increased aromatase expression and estradiol level in the brain.
Or it could be the other way around. Neurodegeneration from Alzheimer's could lead to increased aromatase expression and estradiol level in the brain.
The implications of this study are clearly a good basis for further investigation into the role of estradiol in various forms of dementia. If the exact effect of estradiol on dementia and AD can be quantified, then the use of the aromatase inhibitor, Myomin, will have a therapeutic application for dementia and AD patients.
Inflammatory cytokines may also play a role in Alzheimer's risk. In the Framingham Heart Study cohort, 691 cognitively intact seniors (62% women, 38% men with a mean age of 79) took part in the study. Among the inflammatory cytokines measured were interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-a).
Results show that those in either the middle third of spontaneous production of IL-1 or top third of TNF-a had a more than 2.5-fold risk for Alzheimer's disease. The researchers acknowledge that these results are limited and preliminary. However, if a definite causal relationship between inflammatory cytokines and Alzheimer's is established, then the supplement, Psoricaid, will be useful for this condition. Psoricaidreduces IL-1 and TNF-a."
Results show that those in either the middle third of spontaneous production of IL-1 or top third of TNF-a had a more than 2.5-fold risk for Alzheimer's disease. The researchers acknowledge that these results are limited and preliminary. However, if a definite causal relationship between inflammatory cytokines and Alzheimer's is established, then the supplement, Psoricaid, will be useful for this condition. Psoricaidreduces IL-1 and TNF-a."
For more information read Dr Chi's HERBAL FORMULAS 2nd Edition by Tsu-Tsair Chi, NMD, PhD "
Full Article and Source
No comments:
Post a Comment